Enimmune Corporation (TPEX:6564)

Market Cap	1.37B +0.5%
Revenue (ttm)	48.19M +20.7%
Net Income	-164.35M
EPS	-2.28
Shares Out	72.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120,282
Average Volume	123,089
Open	18.85
Previous Close	18.95
Day's Range	18.40 - 18.95
52-Week Range	14.65 - 23.90
Beta	0.33
RSI	52.14
Earnings Date	Aug 11, 2026

About Enimmune

Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, whic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 38
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6564

Financial Performance

In 2025, Enimmune's revenue was 48.19 million, an increase of 20.74% compared to the previous year's 39.92 million. Losses were -164.35 million, 4.32% more than in 2024.